PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials

BMJ Open Respir Res · 2022 · PMC9472163

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

The OS analysis was immature with a slight trend favouring nivolumab combination.

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.